GuidelineMagyar onkologia2025
[Hereditary genetic testing and its application in the diagnosis, treatment, and prevention of breast cancer].
Guideline in Magyar onkologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo formulate standardized recommendations for recognizing and managing the genetic risk of breast cancer, based on the latest scientific evidence and clinical experience.
methodsThe authors adapted international professional guidelines to local conditions, which were reviewed within the framework of the 5th Hungarian Breast Cancer Consensus Conference.
resultsThe consensus document provides detailed guidance on the indications for genetic testing, the process of clinical genetic counseling, and hereditary genetic testing in breast cancer patients. Given their prevalence and importance, separate chapters address breast, ovarian, and other cancer risks in carriers of pathogenic or likely pathogenic BRCA1/2 variants, along with related screening, prevention, and management recommendations, including risk-reducing surgery, chemoprevention, and hormone replacement therapy. The consensus also covers risk assessment and management in carriers of other high-penetrance gene variants (CDH1, PALB2, PTEN, STK11, TP53), as well as the role of moderate-penetrance genes.
conclusionsThis consensus provides a unified professional framework for genetic risk assessment and management in national practice, supporting personalized patient care and contributing to the early detection and prevention of hereditary breast and ovarian cancer.
Indexed as
Identifiers
41002090PMC12495544What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.